Skip to main content

Advertisement

SpringerLink
Log in

Aspirin and Heparin in Acute Ischaemic Stroke in Older Patients

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Over four-fifths of all strokes are due to thrombotic or embolic occlusion of cerebral arteries. There is a strong rationale for considering antithrombotic therapy for the treatment of patients with acute ischaemic stroke. Antiplatelet therapy with 150 to 300mg of aspirin (acetylsalicylic acid) started within the first 48 hours of an ischaemic stroke improves patient outcome in the short and long term, with a low risk of adverse effects. Anticoagulants such as heparin may reduce the risk of developing deep venous thrombosis and pulmonary embolism in patients with stroke, but randomised controlled trials have demonstrated a significant and dose-dependent risk of intracranial haemorrhage. The routine use of parenteral anticoagulants, including unfractionated heparin, low-molecular-weight heparins and heparinoids in the acute phase of ischaemic stroke is not associated with any net short or long term benefit. Aspirin is, therefore, the antithrombotic drug of choice in the treatment of acute ischaemic stroke.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease study. Lancet 1997; 349: 1269–76

    Article  PubMed  CAS  Google Scholar 

  2. Bonita R. Epidemiology of stroke. Lancet 1992; 339 (8789) 342–4

    Article  PubMed  CAS  Google Scholar 

  3. Bamford J, Sandercock P, Dennis M, et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project, 1981–1986: 1. Methodology, demography and incident cases of first ever stroke. J Neurol Neurosurg Psychiatry 1988; 51: 1373–80

    Article  PubMed  CAS  Google Scholar 

  4. Bamford J, Sandercock P, Dennis M, et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project, 1981–1986. J Neurol Neurosurg Psychiatry 1990; 53: 16–22

    Article  PubMed  CAS  Google Scholar 

  5. Bamford J, Dennis M, Sandercock P, et al. The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. J Neurol Neurosurg Psychiatry 1990; 53: 824–9

    Article  PubMed  CAS  Google Scholar 

  6. Wade DT. Functional abilities after stroke: measurement, natural history and prognosis. J Neurol Neurosurg Psychiatry 1988; 52: 236–41

    Google Scholar 

  7. Bergman L, van de Meulen JHP, Limburg M, et al. Costs of medical care after first-ever stroke in the Netherlands. Stroke 1995; 26: 1830–6

    Article  PubMed  CAS  Google Scholar 

  8. Stroke Unit Trialists Collaboration. Organised inpatient (stroke unit) care for stroke: Cochrane review. In: The Cochrane Library. Issue 1. Oxford: Update Software Ltd., 1999

    Google Scholar 

  9. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997; 350: 607–14

    Article  PubMed  CAS  Google Scholar 

  10. Fontanarosa P, Winker M. Timely and appropriate treatment for acute stroke: whats missing from this picture. JAMA 1998; 279: 1307–8

    Article  PubMed  CAS  Google Scholar 

  11. The Royal College of Physicians of Edinburgh. Royal College of Physicians of Edinburgh consensus conference on medical management of stroke, 26 and 27 May 1998. J Neurol Neurosurg Psychiatry 1999; 66 (1): 128–9

    Article  Google Scholar 

  12. The European Ad Hoc Consensus Group. Neuroprotection as initial therapy in acute stroke. Cerebrovasc Dis 1998; 8: 59–72

    Article  Google Scholar 

  13. Cochrane Stroke Group. Collaborative review group search strategy. In: The Cochrane Library. Issue 1. Oxford: Update Software Ltd, 1999

    Google Scholar 

  14. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–94

    Article  PubMed  CAS  Google Scholar 

  15. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235–46

    Article  Google Scholar 

  16. Gubitz G, Sandercock P, Counsell C. Antiplatelet therapy for acute ischaemic stroke: Cochrane review. In: The Cochrane Library. Issue 2. Oxford: Update Software Ltd, 1999

    Google Scholar 

  17. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, heparin, both or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569–81

    Article  Google Scholar 

  18. Chinese Acute Stroke Trial (CAST) Collaborative Group. CAST: Randomised placebo controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641–9

    Article  Google Scholar 

  19. Multicentre Acute Stroke Trial — Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509–14

    Google Scholar 

  20. Warlow CP, Dennis MS, van Gijn J, et al. In: Warlow CP, Dennis MS, van Gijn J, et al. (editors). Stroke: a practical guide to management. Oxford: Blackwell Science, 1996: 550

  21. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106

    Article  Google Scholar 

  22. Scottish Intercollegiate Guidelines Network (SIGN). Management of patients with stroke I: assessment, investigation, immediate management and secondary prevention [online]. Available from: URL: http://www.pc47.cee.hw.ac.uk/sign/home.htm

  23. Slattery J, Warlow CP, Shorrock CJ, et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin: analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37: 509–11

    Article  PubMed  CAS  Google Scholar 

  24. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, et al., editors. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: JB Lippincott Co., 1994: 837–60

    Google Scholar 

  25. Sandercock PA, van den Belt AG, Lindley RI, et al. Antithrombotic therapy in acute ischaemic stroke: an overview of the randomised trials. J Neurol Neurosurg Psychiatry 1993: 56; 17–25

    Article  PubMed  CAS  Google Scholar 

  26. Gubitz G, Sandercock P, Counsell C, et al. Anticoagulants for acute ischaemic stroke: Cochrane review. In: The Cochrane Library. Issue 2. Oxford: Update Software Ltd, 1999

    Google Scholar 

  27. Hakim AM, Furlan AJ, Hart RG, The Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983; 14: 668–76

    Article  Google Scholar 

  28. Duke RJ, Bloch RF, Turpie AGG, et al. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986; 105: 825–8

    PubMed  CAS  Google Scholar 

  29. Kay R, Wong KS, Lu YL, et al. The Fraxiparine in Ischaemic Stroke Study (FISS) trial: low molecular weight heparin for the treatment of acute stroke. N Engl J Med 1995; 333: 1588–93

    Article  PubMed  CAS  Google Scholar 

  30. Hommel M, for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS-bis) [abstract]. Cerebrovasc Dis 1998; 8 Suppl. 4: 19

    Google Scholar 

  31. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid ORG 10172 (danaparoid), and outcome after acute ischaemic stroke. JAMA 1998; 279: 1265–72

    Article  Google Scholar 

  32. Gubitz G, Sandercock P, Counsell C. Different doses of anticoagulants for acute ischaemic stroke: Cochrane review protocol. In press

  33. Wells PS, Lensing AWA, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism: a meta-analysis. Arch Intern Med 1994; 154: 67–72

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurosciences Trials Unit, Department of Clinical Neurosciences, The University of Edinburgh, Bramwell Dott Building, Western General Hospitals NHS Trust, Crewe Road, Edinburgh, EH4 2XU, Scotland

    Gordon J. Gubitz & Peter A. G. Sandercock

Authors
  1. Gordon J. Gubitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter A. G. Sandercock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gordon J. Gubitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gubitz, G.J., Sandercock, P.A.G. Aspirin and Heparin in Acute Ischaemic Stroke in Older Patients. Drugs & Aging 15, 29–36 (1999). https://doi.org/10.2165/00002512-199915010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915010-00003

Keywords

Search

Navigation